Gene therapy in the management of Erectile Dysfunction (ED): Past, present, and future

11Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the past, many researchers considered viral vectors to be the most promising candidates to transfer genetic material into the corpora for the treatment of erectile dysfunction. However, at present, no viral vectors have progressed to human trials. In contrast, the use of naked gene therapy, a plasmid expressing the human Maxi-K potassium channel, is the only gene therapy treatment to be evaluated in clinical phase I trials to date. The success of these studies, proving the safety of this treatment, has paved the way for the development of future gene transfer techniques based on similar transfer methods, as well as novel treatment vectors, such as stem cell transfer. ©2009 with author. Published by TheScientificWorld.

Cite

CITATION STYLE

APA

Melman, A., & Davies, K. P. (2009, August 31). Gene therapy in the management of Erectile Dysfunction (ED): Past, present, and future. TheScientificWorldJournal. https://doi.org/10.1100/tsw.2009.102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free